Author:
Graziottin Alessandra,Murina Filippo
Publisher
Springer International Publishing
Reference59 articles.
1. Abraham L, Pinkerton JV, Messig M, Ryan KA, Komm BS, Mirkin S. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. Maturitas. 2014;78(3):212–8. doi: 10.1016/j.maturitas.2014.04.008 . Epub 2014 Apr 26.
2. Alkatout I, Schubert M, Garbrecht N, Weigel MT, Jonat W, Mundhenke C, Gunther V. Vulvar cancer: epidemiology, clinical presentation, and management options. Int J Womens Health. 2015;7:305–13. doi: 10.2147/IJWH.S68979 . eCollection 2015.
3. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010;13(2):132–40.
4. Bouchard C, Labrie F, Derogatis L, Girard G, Ayotte N, Gallagher J, Cusan L, Archer DF, Portman D, Lavoie L, Beauregard A, Côté I, Martel C, Vaillancourt M, Balser J, Moyneur E, other participating Members of the VVA Prasterone Group. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm Mol Biol Clin Investig. 2016;25(3):181–90.
5. Bruyniks N, Nappi RE, Castelo-Branco C, de Villiers TJ, Simon J. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric. 2016;19(1):60–5.